Nasonex安鼻適

Nasonex

mometasone

Manufacturer:

MSD

Distributor:

Zuellig
/
Agencia Lei Va Hong

Marketer:

A. Menarini
Concise Prescribing Info
Contents
Mometasone furoate
Indications/Uses
Symptomatic treatment of seasonal or perennial rhinitis in adults, adolescents, & childn 2-11 yr. Prophylactic treatment in patients who have history of moderate to severe symptoms of seasonal allergic rhinitis. Adjunctive treatment to antibiotics for acute episodes of sinusitis in adults & adolescents ≥12 yr. Treatment of nasal polyps in adults ≥18 yr. Symptomatic treatment of acute rhinosinusitis in patients ≥ 12 yr w/o signs or symptoms of severe bacterial infection.
Dosage/Direction for Use
Prophylaxis or treatment of seasonal allergic or perennial rhinitis Adult (including the elderly) & adolescent 2 sprays (50 mcg/spray) in each nostril once daily (total dose 200 mcg). Maintenance: 1 spray in each nostril (total dose 100 mcg) once symptoms are controlled. If symptoms are inadequately controlled, dose may be increased to max daily dose of 4 sprays in each nostril once daily (total 400 mcg). Childn 2-11 yr 1 spray in each nostril once daily (total dose 100 mcg). Adjunctive treatment of acute episodes of sinusitis Adult (including the elderly) & adolescent ≥12 yr 2 sprays in each nostril bd (total dose 400 mcg), may be increased to 4 sprays in each nostril bd (total dose 800 mcg) if symptoms are inadequately controlled. Nasal polyposis Adult (including the elderly) & adolescent ≥18 yr 2 sprays in each nostril once daily (total dose 200 mcg), may be increased to 2 sprays in each nostril bd (total dose 400 mcg) if symptoms are inadequately controlled after 5-6 wk. Acute rhinosinusitis Adult & adolescent ≥12 yr 2 sprays in each nostril bd (total dose 400 mcg).
Contraindications
Special Precautions
Should not be used in the presence of untreated localized infection involving the nasal mucosa. Do not use in patients who have experienced recent nasal surgery or trauma until healing has occurred. Periodically examine for possible changes in the nasal mucosa in case of long-term treatment. Use w/ caution in patients w/ active or quiescent TB infections of the resp tract, or in untreated fungal, bacterial, systemic viral infections or ocular herpes simplex. Potentially immunosuppressed patients should be warned of the risk of exposure to certain infections. Reports of nasal septum perforation or increased IOP; visual disturbance. Treatment of unilateral polyps, polyps associated w/ cystic fibrosis, or polyps that completely obstruct the nasal cavities; nasal polyposis in childn & adolescents <18 yr; symptoms of rhinosinusitis in childn <12 yr. Pregnancy & lactation.
Adverse Reactions
Headache, epistaxis, pharyngitis, nasal burning, irritation & ulceration; upper resp tract infection.
Drug Interactions
Possible increased risk of side effects w/ CYP3A inhibitors, including cobicistat-containing products.
ATC Classification
R01AD09 - mometasone ; Belongs to the class of topical corticosteroids used for prophylaxis and treatment of allergic rhinitis.
Presentation/Packing
Form
Nasonex nasal spray 0.05 %
Packing/Price
140 metered dose x 1's;60 metered dose x 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in